Immuno-Oncology
Immune cells have the capability to eliminate tumor cells; however, tumor cells can develop the ability to evade immune responses. Current research efforts have been focused on developing personalized strategies for cancer treatment and developing new therapies that bolster the immune response in the fight against tumor cells.
Below is a collection of scientific resources for your immuno-oncology research.
Featured
Production of Chimeric Antigen Receptor T Cells
This free Nature Protocols Wallchart summarizes the processes involved in producing CAR T cells for therapy.
Get Your Free Copy >-
How to Characterize Extracellular Vesicles by Western BlottingHow to characterize extracellular vesicles and analyze for presence of characteristic EV protein markers by western blotting -
Importance of Using an FcR Blocker During Cell Separation ProceduresEasySep™ Other Species indirect selection kits can be used to isolate cells from any species -
Using Cell Density Gradients to Optimize Your Cell IsolationsRosetteSep™, a unique immunodensity cell isolation platform, isolates highly purified cells by density gradient centrifugation without columns or magnets -
Non-Viral CRISPR Knock-In Anti-B7-H3 CAR-T Cells Are Amenable for Treatment of Subtypes of Small Cell Lung CancerIn this webinar, Scientist Vimal Keerthi discusses his work on identifying CD276 (B7-H3) overexpression in primary human SCLC and developing a non-viral CRISPR-Cas9 knock-in (CKI) based platform against B7-H3 to manufacture CAR T cells for the treatment of SCLC. He demonstrates the feasibility of this CAR T manufacturing platform and how this provides a blueprint for immediate clinical translation, overcoming the bottleneck of viral vector production.<br><br>This webinar is part of the “Translational T Cell Talks: Scaling for the Future” event hosted in collaboration with Scientist.com on June 11, 2024. <a href="/translational-t-cell-talks-2024">View the rest of the talks and read the Q&A transcripts.</a> -
Bhushan Dharmadhikari, PhDDr. Bhushan Dharmadhikari shares his work studying dendritic cells and their applications in cancer immunology and immunotherapy -
Preparing a Polymorphonuclear Cell Fraction from Whole Blood using Ammonium Chloride LysisTechnical tip from our dedicated team of Product and Scientific Support specialists -
Sara McKee, PhDDr. Sara McKee discusses her research on antibody-based immunotherapy for B cell lymphoma -
Natural Killer CellsOverview of NK cell receptors, subsets, activation and function -
Production of Chimeric Antigen Receptor T CellsThis free Nature Protocols Wallchart summarizes the processes involved in producing CAR T cells for therapy. -
How to Optimize Your T Cell Therapy Workflow—Without the Use of Serum or Feeder CellsIn this talk, Dr. Dominika Nackiewicz introduces how ϳԹ can help optimize your T cell cultures with robust, high-performance products and expert support. You will learn how to generate high yields of functional T cells for cell therapy development and manufacturing using the new GMP ImmunoCult™ medium and activators. She will also discuss efficient gene editing strategies using the new CellPore™ Transfection System and solutions for T cell generation from pluripotent stem cells or hematopoietic stem and progenitor cells.<br><br>This webinar is part of the “Translational T Cell Talks: Scaling for the Future” event hosted in collaboration with Scientist.com on June 11, 2024. <a href="/translational-t-cell-talks-2024">View the rest of the talks and read the Q&A transcripts.</a> -
Advances in Point-of-Care Cell Engineering—What Are You Feeding Your CAR T Cells?In this webinar, Dr. Julian J. Lum discusses key factors to consider when choosing metabolic assays and how they can be used to assess cell function. Additionally, he discusses the metabolic characteristics of different commercially available cell culture media formulations as well as the importance of assessing the array of media products and their impact on metabolism.<br><br>This webinar is part of the “Translational T Cell Talks: Scaling for the Future” event hosted in collaboration with Scientist.com on June 11, 2024. <a href="/translational-t-cell-talks-2024">View the rest of the talks and read the Q&A transcripts.</a> -
Combining CAR T Cells with STING Agonists to Fight Solid TumorsIn this webinar, Dr. Uslu describes how IMSA101 enhances CAR T function through STING agonist-induced IL-18 secretion and how these findings lay the foundation for advancing the combinatorial approach into a clinical setting.<br><br>This webinar is part of the “Translational T Cell Talks: Scaling for the Future” event hosted in collaboration with Scientist.com on June 11, 2024. <a href="/translational-t-cell-talks-2024">View the rest of the talks and read the Q&A transcripts.</a>
